European Journal of Internal Medicine
Volume 19, Issue 3 , Pages 209-213 , May 2008

Classical cardiovascular risk factors according to fasting plasma glucose levels

  • Sergio Martinez-Hervas

      Affiliations

    • Endocrinology Service, University Clinical Hospital, Department of Medicine—University of Valencia, Spain
    • Corresponding Author InformationCorresponding author. S. Endocrinología, Hospital Clínico Universitario de Valencia, Avda Blasco Ibanez 17, 46010 Valencia, Spain. Tel.: +34 96 3862665; fax: +34 96 3862665.
    • ,
  • Pedro Romero

      Affiliations

    • Center for Primary Care, Valencia, Spain
    • ,
  • Enrique B. Hevilla

      Affiliations

    • Department of Preventive Medicine and Public Health, University of Valencia & University Clinical Hospital, Valencia, Spain
    • ,
  • José T. Real

      Affiliations

    • Endocrinology Service, University Clinical Hospital, Department of Medicine—University of Valencia, Spain
    • ,
  • Antonia Priego

      Affiliations

    • Endocrinology Service, University Clinical Hospital, Department of Medicine—University of Valencia, Spain
    • ,
  • Jose M. Martin-Moreno

      Affiliations

    • Department of Preventive Medicine and Public Health, University of Valencia & University Clinical Hospital, Valencia, Spain
    • ,
  • Rafael Carmena

      Affiliations

    • Endocrinology Service, University Clinical Hospital, Department of Medicine—University of Valencia, Spain
    • ,
  • Juan F. Ascaso

      Affiliations

    • Endocrinology Service, University Clinical Hospital, Department of Medicine—University of Valencia, Spain

Received 24 April 2007 ,Revised 29 June 2007 ,Accepted 27 September 2007.

References 

  1. American Diabetes Association . Standards of medical care in diabetes. Diabetes Care. 2004;1:S15–S35Suppl
  2. Sattar N, Williams K, Sniderman AD, D'Agostino R, Haffner SM. Non-high-density lipoprotein cholesterol with other cardiovascular risk factors in patients with the metabolic syndrome in the insulin resistance atherosclerosis study. Circulation. 2004;110:2687–2693
  3. Despres JP, Lamarche B, Mauriege P, Cantin B, Dagenais GR, Moorjani S, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N. Engl. J. Med. 1996;334:952–957
  4. McGarry JD. What if Minkowski had been ageusic? An alternative angle on diabetes. Science. 1992;258:766–774
  5. Ascaso JF, Romero P, Real JT, Lorente RI, Martínez-Valls J, Carmena R. Abdominal adiposity (waist circumference) and its relation to insulin resistance and the metabolic syndrome in a South European Population. Eur. J. Intern. Med. 2003;14:101–106
  6. Allain CC, Poon LS, Chan CSG, Richmod W, Fu PC. Enzymatic determination of total serum cholesterol. Clin. Chem. 1979;20:470–475
  7. Ter HF, Baarscheer T, Fiolet JWT. Influence of free glycerol on enzymatic of triglycerides. Clin. Chem. 1984;30:1102–1103
  8. Rosseneau M, Verchemst R, Steinberg KK, Cooper GR. Some considerations of methodology and standardization of apolipoprotein B immunoassays. Clin. Chem. 1983;29:427–433
  9. Trinder P. Enzymatic colorimetric method for glucose determination. Ann. Clin. Biochem. 1969;6:24–27
  10. Berson S, Yellow RS. Quantitative aspects of the reaction between insulin and insulin-binding antibody. J. Clin. Invest. 1959;38:1996–2016
  11. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Teacher DF, Turner RC. Homeostasis model assessment: insulin resistance and B cell function from fasting plasma glucose and insulin concentration in man. Diabetologia. 1985;28:412–419
  12. Ascaso JF, Romero P, Real JT, Priego A, Valdecabres C, Carmena R. nsulin resistance quantification by fasting insulin plasma values and HOMA index in a non-diabetic population. Med. Clin. (Barc). 2001;117:530–533
  13. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA. 2001;285:2486–2497
  14. Tamayo B, Faure E, Roche MJ, Rubio E, Sánchez E, Salvador JA. Prevalence of diabetes and impaired glucose tolerance in Aragon, Spain. Diabetes Care. 1977;20:534–536
  15. Diabetes Prevention Program Research Group. Strategies to identify adults at high risk for type 2 diabetes: the Diabetes Prevention Program. Diabetes Care. 2005;28:138–144
  16. de Pablos-Velasco PL, Martínez-Martín FJ, Rodríguez-Pérez F, Anía BJ, Losada A, Betancor P. Guia Study. Prevalence and determinants of diabetes mellitus and glucose intolerance in a Canarian Caucasian population—comparison of the 1997 ADA and the 1985 WHO criteria. The Guía Study. Diabet. Med. Mar 18 2001;(3):235–241
  17. Heldgaard PE, Olivarius N de F, Hindsberger C, Henriksen JE. Impaired fasting glycaemia resembles impaired glucose tolerance with regard to cardiovascular risk factors: population-based, cross-sectional study of risk factors for cardiovascular disease. Diabet. Med. 2004;21:363–370
  18. Bartnik M, Rydén L, Ferrari R, Malmberg K, Pyörälä K, Simoons M, et al. Euro Heart Survey Investigators. The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. Eur. Heart J. 2004;25:1880–1890
  19. Malik S, Wong ND, Franklin SS, Kamath TV, L'Italien GJ, Pio JR, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation. 2004;110:1245–1250
  20. Wang J, Ruotsalainen S, Moilanen L, Lepistö P, Laakso M, Kuusisto J. The metabolic syndrome predicts cardiovascular mortality: a 13-year follow-up study in elderly non-diabetic Finns. Eur. Heart J. 2007;28:857–864
  21. Kanaya AM, Herrington D, Vittinghoff E, Lin F, Bittner V, Cauley JA, et al. Impaired fasting glucose and cardiovascular outcomes in postmenopausal women with coronary artery disease. Ann. Intern. Med. 2005;142:813–820
  22. Rijkelijkhuizen JM, Nijpels G, Heine RJ, Bouter LM, Stehouwer CDA, Dekker JM. High risk cardiovascular mortality in individuals with impaired fasting glucose is explained by conversion to diabetes. The Hoorn Study. Diabetes Care. 2007;30:332–336
  23. Forouhi NG, Balkau B, Borch-Johnsen K, Dekker J, Glumer C, Qiao Q, et al. EDEG. The threshold for diagnosing impaired fasting glucose: a position statement by the European Diabetes Epidemiology Group. Diabetologia. 2006;49:822–827
  24. Haffner SM, Gonzalez C, Miettinen H, Kennedy E, Stern MP. A prospective analysis of the HOMA model. The Mexico City Diabetes Study. Diabetes care. 1996;19:1138–1141
  25. Kashiwabara H, Inaba M, Maruno Y, Morita T, Awata T, Negishi K, et al. Insulin levels during fasting and the glucose tolerance test and HOMA's index predict subsequent development of hypertension. J. Hypertens. 2000;18:83–88
  26. Solymoss BC, Bourassa MG, Campeau L, Sniderman A, Marcil M, Lesperance J, et al. Effect of increasing metabolic syndrome score on atherosclerotic risk profile and coronary artery disease angiographic severity. Am. J. Cardiol. 2004;93:159–164
  27. Meigs JB, Larson MG, D'Agostino RB, Levy D, Clouse ME, Nathan DM, et al. Coronary artery calcification in type 2 diabetes and insulin resistance. The Framingham Offspring Study. Diabetes Care. 2002;25:1313–1319

PII: S0953-6205(07)00264-6

doi: 10.1016/j.ejim.2007.09.005

European Journal of Internal Medicine
Volume 19, Issue 3 , Pages 209-213 , May 2008

Article Tools

* Image Usage & Resolution